Meg Jardine @Meg_Jardine@med-mastodon.com Profile
Meg Jardine @[email protected]

@jardine_meg

Followers
1K
Following
1K
Statuses
363

Director NHMRC Clinical Trials Centre, Professor of Medicine, Nephrologist, Trialist

Sydney, New South Wales
Joined April 2019
Don't wanna be here? Send us removal request.
@jardine_meg
Meg Jardine @[email protected]
5 months
Truly inspirational. Wonderful to hear some of the insights on trial that saved a million lives in a year. A tribute to the many different organisations involved. Can we harness this same collaborative approach to addressing the epidemic of chronic disease?
@TrialsCentre
NHMRC CTC
5 months
What does it take to revolutionise COVID-19 treatment? Yesterday, we found out! We hosted Prof. @RichardHaynes3, who shared insights from the #RECOVERYTrial, the world’s largest #COVID19 treatment trial. His exploration of the trial’s design, methodology, and key findings was enlightening. Thank you, Richard, for an inspiring session!
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
9
@jardine_meg
Meg Jardine @[email protected]
7 months
Great summary of clinical effects, mechanisms of action and health economic evaluations led by @Daniel_V_OHara
@NatRevNeph
Nature Reviews Nephrology
8 months
Applications of SGLT2 inhibitors beyond glycaemic control from @jardine_meg and colleagues
0
3
11
@jardine_meg
Meg Jardine @[email protected]
8 months
RT @ISNkidneycare: 📢 Call for Nominations Nominate the next ISN: 👤President-Elect & 👥Regional Board Deputy Chairs/Council members for all…
0
4
0
@jardine_meg
Meg Jardine @[email protected]
9 months
RT @KidneyHealth: The only way to slow down #kidneydisease is to catch it early, before symptoms appear.​ Take the 2min risk test online no…
0
7
0
@jardine_meg
Meg Jardine @[email protected]
9 months
RT @CJASN: Angiopoietin 2 regulates endothelial function partially mediated by VEGF-A. This study found higher angiopoietin 2 levels were a…
0
5
0
@jardine_meg
Meg Jardine @[email protected]
9 months
@TrialsCentre Fantastic summary of a field that has exploded. Great work from #ISN Emerging Leader Program Fellow, #ISN-ELP, @Daniel_V_OHara
0
1
4
@jardine_meg
Meg Jardine @[email protected]
9 months
RT @TrialsCentre: 📢 Prepare for the new treatment landscape 📢 #SGLT2 inhibitors are foundational for prevention & treatment of complicatio…
0
2
0
@jardine_meg
Meg Jardine @[email protected]
9 months
RT @RachaelMorton12: Did you know the NHMRC @TrialsCentre is now conducting 20 adaptive platform trials. Congratulations to all academic an…
0
2
0
@jardine_meg
Meg Jardine @[email protected]
9 months
0
0
6
@jardine_meg
Meg Jardine @[email protected]
10 months
Had a fantastic time at the InaSN meeting discussing the latest #KDIGO_CKD_Guidelines. With new therapies, access & implementation now a key focus. @NephJC will also be discussing - online May 21/22 Thanks to Dr Pringgo & team for a warm welcome and to #ISN for support
@inasn_pernefri
InaSN - PERNEFRI
10 months
Huge thanks to Prof. @jardine_meg for her enlightening talk on the latest KDIGO CKD guidelines at the 23rd Jakarta Nephrology and Hypertension Course, hosted by the Indonesia Society of Nephrology. The event in Jakarta was a success, enhanced by the support of ISN and KDIGO.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
2
13
@jardine_meg
Meg Jardine @[email protected]
11 months
Always fun and informative to chat with Rajiv!
@theCMforum
The Cardiometabolic Forum
1 year
NEW PODCAST 📻 Catch up on the #ASN2023 highlights with Professors @Jardine_Meg and @AgarwalRajivMD over on the CMF! Access here via soundcloud: Access here via youtube:
Tweet media one
0
0
2
@jardine_meg
Meg Jardine @[email protected]
11 months
An exciting time for kidney disease with lots of new therapies on the horizon. #KidneyHealthForAll is a timely reminder that we need to ensure equitable access as these emerge @ISNkidneycare; @KidneyHealth @KidneyHealthIn
@TrialsCentre
NHMRC CTC
11 months
Happy #WorldKidneyDay! This year's theme is #KidneyHealthForAll: Advancing Equitable Access to Care and Optimal Medication Practice. We're working towards a future where everyone has access to quality care for their kidneys. 💪🏽👨🏼‍⚕️👩🏾‍⚕️ Learn more here:
Tweet media one
1
2
15
@jardine_meg
Meg Jardine @[email protected]
1 year
RT @JASN_News: Excess mortality in HD patients is associated with abnormal fluid status and plasma sodium concentrations. This study stress…
0
5
0
@jardine_meg
Meg Jardine @[email protected]
1 year
@so_jcc @sagarnigs Very sorry to learn of your loss. My deepest condolences
0
0
0
@jardine_meg
Meg Jardine @[email protected]
1 year
Thank-you! Including first author @brendanjsmyth. Worth reading the original article led by @JulePinter Challenging - observational evidence is confounded & can be difficult to interpret. An eg of where randomisation is needed for true quality assessment
@Renaltubules
Airawat ऐरावत
1 year
1
0
4
@jardine_meg
Meg Jardine @[email protected]
1 year
@TrialsCentre @ISNkidneycare @Sydney_Uni @Daniel_V_OHara @MelanieWyl22998 @UNSW Congratulations to all the cohort. It's a great program!
0
1
1
@jardine_meg
Meg Jardine @[email protected]
1 year
@so_jcc Disappointingly little proven evidence for calciphylaxis. It's why trials are so important. I'm not aware of a registry in the US. @sagarnigs may know more
3
1
1
@jardine_meg
Meg Jardine @[email protected]
1 year
That can be a challenge. The concept is - will receive one of a number of interventions or placebo. If not getting better after 4 weeks, will get an active treatment (but you won't know which one). #NephTrials
0
1
5
@jardine_meg
Meg Jardine @[email protected]
1 year
Yes! Great work from @BerryConsultant Liz Lorenzi. #NephTrials
0
0
6